Price$108.44+0.25 (+0.24%)
01:30 PM07:45 PM
News · 26 weeks47-42%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- SEC Filings8(30%)
- Other5(19%)
- Earnings2(7%)
- Leadership1(4%)
Latest news
25 items- PRAZENTA ANNOUNCES LEADERSHIP TRANSITIONCurrent Director Dr. Martin Madaus Appointed Interim CEOCompany Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue GuidanceBURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.Dr. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 – making him the ideal individual to lead the Company during this transition. He is a Senior O
- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - HAEMONETICS CORP (0000313143) (Filer)
- SECSEC Form S-8 filed by Haemonetics CorporationS-8 - HAEMONETICS CORP (0000313143) (Filer)
- SECSEC Form 10-Q filed by Haemonetics Corporation10-Q - HAEMONETICS CORP (0000313143) (Filer)
- SECHaemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations WebsiteFinancial release and supplemental presentation accessible onlineBOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the eve
- PRNew Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore SheathsBOSTON, Aug. 3, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced publication of a study providing new evidence supporting the safety and efficacy of Haemonetics' VASCADE MVP® XL venous vascular closure system in large-bore sheath procedures. The retrospective cohort study represents the largest reported cohort using the VASCADE MVP XL system to date.Conducted at Emory University and funded by a grant from Haemonetics, the single center retrospective study by an experienced user evaluated real-world outcomes in 1,623 patients who received the VASCADE MVP
- INSIDERDirector Madaus Martin D was granted 2,538 shares (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Zane Ellen M was granted 2,538 shares, increasing direct ownership by 13% to 21,911 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Pomeroy Claire was granted 2,538 shares, increasing direct ownership by 15% to 19,410 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Kroll Mark W was granted 2,538 shares, increasing direct ownership by 10% to 27,295 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Johnson Lloyd Emerson was granted 2,538 shares, increasing direct ownership by 20% to 15,471 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Coyle Michael J was granted 2,538 shares, increasing direct ownership by 16% to 17,932 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Bryant Diane M was granted 2,538 shares, increasing direct ownership by 36% to 9,664 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERDirector Abernathy Robert E was granted 2,538 shares, increasing direct ownership by 10% to 27,519 units (SEC Form 4)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERSEC Form 3 filed by new insider Madaus Martin D3 - HAEMONETICS CORP (0000313143) (Issuer)
- SECHaemonetics Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRMartin Madaus Elected to Haemonetics Board of DirectorsBOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that Martin Madaus has been elected to the Company's Board of Directors, effective July 24, 2026.Dr. Madaus brings more than 30 years of leadership experience in the diagnostics and life sciences tools industries, having helped drive corporate strategy, commercial growth and operational transformation as both a chief executive officer and a board member. He currently serves as Senior Operating Executive at The Carlyle Group, where since 2019 he has advised on healthcare investments an
- PRHaemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.The call can be accessed via teleconference at: Q1 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.A live webcast of the
- SECSEC Form DEFA14A filed by Haemonetics CorporationDEFA14A - HAEMONETICS CORP (0000313143) (Filer)
- SECSEC Form DEF 14A filed by Haemonetics CorporationDEF 14A - HAEMONETICS CORP (0000313143) (Filer)
- INSIDERVP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 259 shares, decreasing direct ownership by 4% to 6,242 units (SEC Form 4) (tax withholding)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERSVP, Human Resources Miller Laurie A. covered exercise/tax liability with 313 shares, decreasing direct ownership by 0.76% to 40,987 units (SEC Form 4) (for withholding tax)4 - HAEMONETICS CORP (0000313143) (Issuer)
- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Updates Financial Reporting SegmentsBOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two. The previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying business
HAE FAQ
7 questionsWhat does Haemonetics Corporation do?
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood...Where does HAE stock trade?
Haemonetics Corporation (HAE) is listed on NYSE.What sector and industry is HAE in?
Haemonetics Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Haemonetics Corporation go public?
Haemonetics Corporation (HAE) completed its IPO in 1991.What are analysts saying about HAE?
Haemonetics Corporation has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-05-22.What companies are similar to HAE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare HAE side-by-side with any of them on Quantisnow.How can I track HAE on Quantisnow?
Quantisnow aggregates Haemonetics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HAE to receive live email and push alerts on every new disclosure.